Barclays Sticks to Its Buy Rating for Kura Oncology (KURA)

Tip Ranks
2025.11.14 09:07

Barclays analyst Etzer Darout maintains a Buy rating for Kura Oncology with a price target of $11.00. Darout, a 5-star analyst, has an average return of 23.7% and a 54.75% success rate. TD Cowen also issued a Buy rating, while BTIG maintained a Hold rating. Darout covers the Healthcare sector, focusing on stocks like Terns Pharmaceuticals and Exelixis.

Barclays analyst Etzer Darout maintained a Buy rating on Kura Oncology today and set a price target of $11.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Darout is a 5-star analyst with an average return of 23.7% and a 54.75% success rate. Darout covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Exelixis, and Arvinas Holding Company.

In addition to Barclays, Kura Oncology also received a Buy from TD Cowen’s Phil Nadeau in a report issued yesterday. However, on November 4, BTIG maintained a Hold rating on Kura Oncology (NASDAQ: KURA).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.